Traders are always on the lookout for lucrative bounce plays, a strategy that capitalizes on stocks with the potential to rebound from recent dips. This approach appeals to investors due to the tempting prospect of big gains. Bounce plays involve studying stock price trends, support levels, and conditions that may indicate undervaluation.
Let's dive into four OTC stocks that could exhibit characteristics hinting at the possibility of a solid rebound, as we kick off this week.
Epazz Inc. (OTC: EPAZ)
EPAZ has recently caught the attention of investors through its groundbreaking collaboration with CryObo Technology, presenting an exciting opportunity for a potential rebound in its stock performance.
At the heart of this collaboration lies the concept of tokenization using NFTs. Epazz Inc. and CryObo Technology offer farmers a unique opportunity to tokenize their crops and produce. Tokenization involves converting real-world assets, such as agricultural produce, into digital tokens on the blockchain. These tokens represent ownership and value, providing farmers with new avenues for revenue generation.
The benefits of tokenization extend beyond capital access. Farmers who adopt this innovative technology can raise immediate capital based on projected future milestones of their crops. This financial flexibility empowers them to make essential investments in their farming operations precisely when needed.
The recent court decision in favor of Ripple has further enhanced the potential for CryObo Technology. The court's decision allows US farmers to benefit from the technology without the need for registration statements, streamlining the adoption process and creating a favorable environment for growth.
Epazz's integration of ZenaDrone 1000 technology is another critical aspect of the collaboration. This advanced aerial data technology equips unmanned aerial vehicles (drones) with the capability to scan fields and accurately assess crop health. Farmers can gain real-time insights into crop conditions, enabling informed decisions on irrigation, fertilization, and weed control. The result is increased productivity and optimized harvest yields.
The issuance of NFT tokens expands Epazz's market reach, providing attractive investment opportunities for farm owners, plantation associations, and agricultural business investors. Token holders stand to receive a share of the income generated from the tokenized crop production, making it a potentially enticing venture for those seeking to invest in the agricultural sector's growth.
Epazz Inc.'s strategic collaboration with CryObo Technology positions the company as a forward-thinking disruptor in multiple industries. By enabling tokenization of agricultural produce and enhancing crop monitoring with advanced drone technology, Epazz empowers farmers, attracts investors, and ushers in a new era of technological innovation in agriculture.
As we explore the potential of Epazz Inc. as a rebound stock, its recent developments and innovative ventures in the agricultural and blockchain industries make it an intriguing candidate for investors looking to capitalize on bounce plays in the market.
On Friday, Aridis Pharmaceuticals Inc. (OTC: ARDS) experienced a 3.85% decline, but this innovative biotech company could be poised for a potential rebound.
With a robust pipeline of multiple clinical-stage mAbs targeting life-threatening infections caused by bacteria and viruses, ADRS is at the forefront of advancing therapies for conditions like ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP).
One of the most promising candidates in their portfolio is AR-301, a fully human IgG1 mAb currently in Phase 3 clinical development. This investigational monoclonal antibody (mAb) is used as an adjunctive therapy for Staphylococcus aureus (S. aureus) pneumonia, a serious pathogen that causes severe infections in hospitalized patients. AR-301 has shown promising antibacterial activity against S. aureus alpha-toxin, which is a key virulence factor secreted by both MRSA and MSSA strains.
What has further fueled investor interest and optimism is the recent positive feedback received from the European Medicines Agency on the clinical study design for AR-301. The agreement on the proposed single confirmatory Phase 3 study, which will include older adults aged 65 and above, has provided a clear regulatory pathway to bring this potential breakthrough therapy to patients at high risk of Staph. aureus infections.
The global harmonization of the clinical study design, endpoints, and patient populations with both the US FDA and EMA further enhances the potential for AR-301's success. Aridis Pharmaceuticals Inc. is actively working towards addressing the deficiencies associated with current standard-of-care antibiotics, such as increasing drug resistance, short duration of efficacy, and disruption of the human microbiome.
Aridis Pharmaceuticals Inc. could hold the potential for a bounce, driven by its groundbreaking anti-infective treatments and the prospects of bringing innovative therapies to combat life-threatening infections.
Fresh Tracks Therapeutics Inc. (Nasdaq: FRTX), a clinical-stage pharmaceutical company, is striving to make a significant impact in the field of healthcare by developing innovative and differentiated prescription therapeutics. Their focus lies in transforming the lives of patients grappling with autoimmune, inflammatory, and other debilitating diseases. With a promising pipeline of new chemical entities targeting novel therapeutic targets, Fresh Tracks aims to disrupt existing treatment paradigms and introduce groundbreaking therapies with first-in-class potential.
Recently, Fresh Tracks made a significant announcement that caught the attention of investors and could potentially lead to a stock rebound. On July 21, 2023, the company revealed that it had entered into an amendment to its Asset Purchase Agreement with Botanix Pharmaceuticals Limited (ASX: BOT) and its subsidiary, Botanix SB Inc. The amendment involves selling its rights to future event-based milestones and earnout payments on net sales of sofpironium bromide to Botanix SB Inc. for an impressive sum of $8.25 million (USD).
The decision to sell these rights was carefully evaluated by the company's Board, and it was deemed to be in the best interests of Fresh Tracks and its shareholders. By opting for this buyout, Fresh Tracks strengthens its financial position with non-equity-dilutive capital, allowing it to explore and evaluate strategic options that can further maximize shareholder value.
Under the terms of the APA Amendment, Botanix will pay $8.25 million in cash, with $6.60 million payable to Fresh Tracks and the remaining $1.65 million payable to the company's former licensor.
This strategic move marks an important milestone for Fresh Tracks as it continues to carve its path in the pharmaceutical landscape. With a focus on developing next-generation therapeutics that address unmet medical needs, Fresh Tracks is positioning itself as a compelling player in the healthcare sector.
On Friday, July 21, 2023, Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company specializing in life-changing therapies for cancer and diabetes patients, experienced a 4.05% decline. However, the company has just announced the successful closing of a registered direct offering, raising approximately $7.5 million in gross proceeds.
The offering, made to healthcare-focused institutional investors, included 7,425,744 shares of Genprex's common stock and accompanying warrants to purchase up to 7,425,744 shares at a combined offering price of $1.01 per share of common stock and warrant. The offering was priced at the market under Nasdaq rules.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. With the net proceeds from this offering, Genprex intends to support working capital and general corporate purposes.
Genprex's focus on developing gene therapies using its proprietary ONCOPREX Nanoparticle Delivery System shows promise in providing novel treatment approaches for patients with cancer and diabetes. Their lead product candidate, REQORSA (quaratusugene ozeplasmid), is currently being evaluated in three clinical trials for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with Fast Track Designation from the Food and Drug Administration.
Despite the recent decline, Genprex's pioneering gene therapy approach and the success of its latest offering position the company as an interesting potential bounce play for investors seeking opportunities in the biotech sector.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Epazz Inc. to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.
CapitalGainsReport
Mark McKelvie
Editor
Markrmckelvie@gmail.com
585-301-7700
.
EPAZZ, INC. 
